Search results
Results from the WOW.Com Content Network
Ibutilide is a Class III antiarrhythmic agent that is indicated for acute cardioconversion of atrial fibrillation and atrial flutter of a recent onset to sinus rhythm. It exerts its antiarrhythmic effect by induction of slow inward sodium current, which prolongs action potential and refractory period of myocardial cells.
For example, although the class III antiarrhythmic agent ibutilide is an effective treatment for atrial flutter, rates of recurrence after treatment are quite high (70–90%). [1] Additionally, there are some specific considerations particular to treatment of atrial flutter.
Class V agents work by other or unknown mechanisms. ... Treat atrial flutter and atrial ... The prolongation of the action potential duration and refractory period ...
[23] [24] Flutter inherits Dart's Pub package manager and software repository, which allows users to publish and use custom packages as well as Flutter-specific plugins. [25] The Foundation library, written in Dart, provides basic classes and functions that are used to construct applications using Flutter, such as APIs to communicate with the ...
Dofetilide is a class III antiarrhythmic agent. [2] It is marketed under the trade name Tikosyn by Pfizer, and is available in the United States in capsules containing 125, 250, and 500 μg of dofetilide. It is not available in Europe [3] or Australia. [4]
There are various classes of agents that are most effective for pharmacological cardioversion. Class I agents are sodium (Na) channel blockers (which slow conduction by blocking the Na+ channel) and are divided into 3 subclasses a, b and c. Class Ia slows phase 0 depolarization in the ventricles and increases the absolute refractory period.
Chocolate eggs dry in the workshop at The Chocolate Line in Bruges, Belgium, Thursday, Feb. 6, 2025. (AP Photo/Virginia Mayo)
The most common indications for digoxin are atrial fibrillation and atrial flutter with rapid ventricular response, [12] [13] especially in older or less active patients, [14] though beta blockers and/or calcium channel blockers may be preferred in some patients, such as younger more active ones, or those without heart failure or hemodynamic instability.